

**FULBRIGHT & JAWORSKI L.L.P.**  
 A REGISTERED LIMITED LIABILITY PARTNERSHIP

666 Fifth Avenue  
 New York, New York 10103-3198  
**FAX: (212) 318-3400**

---

**FACSIMILE COVER SHEET**

---

PLEASE TRANSMIT THE FOLLOWING PAGES TO:

**NAME:** Examiner P. Gamble

**COMPANY/FIRM  
(LOCATION):** U.S. Patent and Trademark Office

**FACSIMILE** (703) 305-7401

**VOICE PHONE:** (703) 308-3997

From:	Norman D. Hanson	Phone No.:	212-318-3168	Number of Pages Sent: (Including Cover Sheet)
Date:	November 13, 2000	User No.:	01030	5
Return Transmitted Fax To:			Flr:	Matter No.:
Annette Crossan			24	09885911
Internet:				nhanson@fulbright.com
Re: LUD-5253.5-DIV				
<b>REMARKS:</b>				

*If you experience problems with this transmission or have questions, please call 212-318-3250.*

**CONFIDENTIALITY NOTICE:** Unless otherwise indicated or obvious from the nature of the transmittal, the information contained in this facsimile message is attorney privileged and confidential information intended for the use of the individual or entity named above. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify the sender by telephone and return the original message to Fulbright & Jaworski L.L.P. at the above address via the U.S. Postal Service at our expense. Thank you.

**CERTIFICATE OF FACSIMILE TRANSMISSION**  
 I hereby certify that this correspondence is being  
 facsimile transmitted to the Commissioner of Patents  
 and Trademarks, Washington, D.C. 20231, on  
November 13, 2000.

FULBRIGHT &amp; JAWORSKI L.L.P.

By Annette Crossan  
 Annette Crossan

TT  
35/T

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s) :	Thierry BOON-FALLEUR et al.	
Serial No. :	08/819,669	OFFICIAL 11/13/00 PAP/AMB
Filed :	March 17, 1997	
For :	TUMOR REJECTION ANTIGEN PRECURSORS, TUMOR REJECTION ANTIGENS AND USES THEREOF	
Art Unit :	1644	
Examiner :	P. Gamble	

November 13, 2000

Hon. Commissioner of Patents  
 and Trademarks  
 Washington, D.C. 20231

OK PC  
 envoi  
 11/13/00

**AMENDMENT  
 UNDER 37  
 CFR § 1.116**

This amendment is responsive to the office action dated September 26, 2000. Please amend applications as follows:

**IN THE SPECIFICATION**

Page 27, next to last line: change "Balb/C" to -- BALB/c --

Page 28, line 3: change "BALB/C" to -- BALB/c --

**IN THE CLAIMS**

Amend claim 176 as follows:

Claim 176 (amended)

The isolated tumor rejection antigen precursor of claim 174, wherein said tumor rejection antigen precursor is encoded by a nucleic acid molecule, the complementary nucleotide sequence of which hybridizes to SEQ ID NO: 8 [, under stringent conditions] at 0.1XSSC, 0.1% SDS.

51